Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Apex Capital’s Standing By Netflix, Inc (NFLX), Other Top Picks

Page 1 of 2

Sanford J. Colen’s Apex Capital, a San Francisco-based long/short equity hedge fund that focuses on U.S.-traded stocks, has filed its 13F with the SEC for the current reporting period. Apex Capital’s three portfolio managers employ a non-consensus strategy to invest in best-of-breed companies with asymmetric risk-reward opportunities. The fund, founded in 1995, invests primarily in the consumer, technology, media and telecommunications (TMT), and healthcare sectors. At the end of the second quarter of 2015, Apex had 30% of the value of its public equity portfolio invested  in consumer discretionary stocks, 27% in healthcare, 21% in information technology, and 14% in industrials. The market value of the fund’s portfolio stood at $1.15 billion at the end of June, representing a decrease of $237.41 million. In this article we’ll take a look at the top picks of the fund heading into the third quarter, which are Netflix, Inc (NASDAQ:NFLX), Michael Kors Holdings Ltd (NYSE:KORS), and Yelp Inc (NYSE:YELP).

Netflix, Inc. (NASDAQ:NFLX), Netflix service, logo, phone, htc, symbol, sign, red

scyther5 /

It is well-known that hedge funds have under-performed the S&P 500 based on net returns over the past several years. But we are missing something very important here. Hedge funds generally pull in strong returns from their top small-cap stocks and invest a lot of their resources into analyzing these stocks. They simply don’t take large enough positions in them relative to their portfolios to generate strong overall returns because their large-cap picks underperform the market. We share the top 15 small-cap stocks favored by the best hedge fund managers every quarter and this strategy has managed to outperform the S&P 500 every year since it was launched in August 2012, returning over 118% and beating the market by more than 60 percentage points (read the details). Because of this, we know that collective hedge fund sentiment is extremely telling and valuable.

Sanford J. Colen
Sanford J. Colen
Apex Capital

It’s position in Netflix, Inc. (NASDAQ:NFLX) stands at the apex of Apex Capital’s portfolio for the fourth consecutive quarter, and by a wide margin, despite the fund selling off 27% of its holding during the second quarter. That left the fund with 1.19 million shares valued at $111.91 million. Netflix, Inc. (Netflix) is the world’s leading Internet television network provider , incorporated in 1997. The US-based Company has over 65 million streaming members in over 50 countries. With a market cap of $45.16 billion, the company has three operating segments: Domestic streaming, International Streaming and Domestic DVD. CEO Reed Hastings aims to have the streaming video service in 200 countries by 2017 and has decided to invest more money into marketing the service outside of the U.S  in the current quarter. Netflix shares are on a torrid run, with equity gains of 58% during the second quarter and over 152% year-to-date. Chase Coleman‘s Tiger Global Management holds just under 18.0 million shares of Netflix, Inc. (NASDAQ:NFLX) as of June 30, with 16.91 million of them being bought during the second quarter. That second quarter investment has made Coleman over $540 million so far in the third quarter, assuming none of it has yet been sold off.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!